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Metabolic regulationThe family of ﬁbroblast growth factors (FGFs) consisting now of 22 members is generally considered to
control a wide range of biological functions such as development, differentiation and survival. However,
research during the past decade provided substantial evidence that a so called “hormone-like” subgroup of
FGFs, comprised of FGF19, FGF21 and FGF23, is involved in the regulation of diverse metabolic pathways to
control glucose, lipid, bile acid, phosphate and vitamin D metabolism. The unique properties of these FGFs
include predominant production of the factors in selective tissues, their abundance in the blood due to the
lack of extracellular heparin-mediated sequestration, and highly speciﬁc tissue-targeted action via
engagement of their respective co-receptors. The important metabolic context of FGF19, FGF21, and FGF23
actions has revealed important novel roles for FGFs and provided signiﬁcant means to explore an opportunity
for therapeutic targeting of these factors and their corresponding pathways.1 3172769574.
v).
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Energy homeostasis is critical for life; therefore diverse hormonal
mechanisms have evolved to regulate cellular energy utilization as
well as inter-tissue communication to coordinate metabolic path-
ways. Although regulation of cellular metabolism bymajor controllers
such as insulin and glucagon is well-established, a new distinct
subgroup of ﬁbroblast growth factors consisting of FGF19, FGF21 and
FGF23, has been recently identiﬁed to play critical roles in the
metabolic network. Within FGF superfamily, these three factors share
the highest level of homology with one another and propagate their
effects via FGFRs, although each of them displays a diversemechanism
of receptor activation. In contrast to classical FGFs that require heparin
for efﬁcient FGFR engagement, FGF19, FGF21 and FGF23 lack
conventional heparin-binding domains. This property allows these
factors to elude body's vast depot of extracellular heparan sulphate
proteoglycans and be readily present in the circulation, thus
putatively function in an endocrine-like manner [1,2].
Despite the absence of heparin-binding domains, FGF19, FGF21
and FGF23 still require cofactors, type 1 transmembrane proteins
Klotho [3] or βKlotho [4], for efﬁcient FGFR activation [5–7]. In
contrast to ubiquitously expressed FGFRs, patterns of Klotho and
βKlotho expression in the body are fairly restricted. Thus, Klotho and
βKlotho, not FGFRs, deﬁne tissue selectivity of action for the
hormone-like FGFs and determine the distinct physiological roles of
these factors: FGF19 regulates cholesterol/bile acid (BA) synthesis,FGF21 controls glucose and lipid metabolism, and FGF23 modulates
phosphate/vitamin D metabolism [8–10].
2. FGF19
Transcripts of FGF19 or its mouse ortholog FGF15 are detected in
brain, cartilage, skin, retina and gall bladder, but are primarily present
in the gut [9,11]. The mechanism of FGFR activation by FGF19 is more
complex than other endocrine FGFs. FGF21 and FGF23 do not bind to
FGFR directly or function in the absence of their corresponding Klotho
cofactors, and their actions are diversely speciﬁc toward βKlotho and
Klotho, respectively [5,6]. In contrast, FGF19 can directly interact with
FGFR4 [12–14], or it may recruit either βKlotho or Klotho as a
coreceptor [7,12]. Indeed, in 293 and 3T3-L1 cells that are devoid of
endogenous FGFR4, forced expression of βKlotho or Klotho is
sufﬁcient to institute FGF19 action [5,12]. Therefore, FGF19 can
speciﬁcally function in a Klotho independent manner but only via
FGFR4, or throughmultiple FGFRs in the context of Klotho coreceptors
expression. FGF19 binds both βKlotho Klotho or via its C-terminus,
while N-terminal part of FGF19 is involved in FGFR interaction and
activation [13].
The initial evidence that FGF19 regulates body metabolism came
from FGF19 transgenic mice. These animals were lean and protected
against diet-induced obesity as a result of elevated energy expendi-
ture, enhanced lipid oxidation and increased brown tissue mass [15].
The FGF19 transgenic mice also displayed lower plasma glucose,
triglycerides and cholesterol, as well as reductions in the levels of the
major metabolic hormones such as insulin, glucagon, leptin and IGF1.
The striking metabolic phenotype in FGF19 overexpressing animals
can be partly explained by changes in liver gene expression. In the
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that are involved in lipogenesis including acetyl CoA carboxylase 2
(ACC2) and stearoyl CoA desaturase 1 (SCD1), as well as decreased
expression of CYP7A1 and CYP8B1 that is involved in cholesterol/BA
synthesis. Comparable pharmacology and molecular events were
recapitulated in naive animals dosed with FGF19 protein [16].
Consistent with FGF19 effect on CYP7A1 and CYP8B1 it is not
surprising that this factor plays an important role in cholesterol/BA
metabolism [9,17,18]. FGF19 production occurs primarily in the ileum
upon bile acid-induced activation of farnesoid X receptor (FXR).
When released into circulation, FGF19 reaches liver and activates
FGFR4 to suppress CYP7A1/8B1 expression leading to a consequent
reduction in BA production [9,17,18]. The existence of a negative
FGF19 (FGF15)/FGFR4 enterohepatic feedback loop that effectively
controls bile acid synthesis is additionally evidenced by elevated
levels of CYP7A1 and BA in livers of both, FGF15 and FGFR4 knockout
animals [9]. The existence of gut-to-liver axis of communication is
further evidenced by the ﬁndings that only intestinal, but not portal
nor intravenous administration of BAs inhibited CYP7A1 expression
and BA production [9]. In man, blood FGF19 levels display well
pronounced diurnal rhythm, with 2.5-fold increase in serum level
after feeding when increase in blood bile acids occurs [19].
Consistent with the phenotypes observed in FGF19 transgenic and
FGF19-treated animals, FGFR4 knockout mice on a normal diet
exhibited features of metabolic syndrome that included increased
adiposity, dyslipidemia, glucose intolerance, insulin resistance as well
as hypercholesterolemia [20]. However, the mechanism by which
FGFR4 is involved in glycemic regulation remains unknown as
reconstitution of this receptor in liver, the main tissue of its
expression, surprisingly did not correct the impaired glucose
homeostasis in FGFR4 knockout mice. It is also unclear why FGFR4
knockout mice are protected from diet-induced fatty liver while
FGF19 is potent in ameliorating hepatosteatosis [20]. Furthermore, it
is intriguing that FGF19 C-terminal deletion mutant that lacks the
ability to activate FGFR1, 2, and 3 due to its inability to bind βKlotho
but still able to act via FGFR4, retained its full hepatic action but failed
to improve glucose control in these mice [21]. Thus, the regulation of
glucose homeostasis by FGF19 may require other FGFRs and/or target
organs beyond liver.
It is rather remarkable that the in vivo pharmacological effects of
FGF19 [15,16] and FGF21 [10,22] in rodents on glucose and lipid
metabolism are nearly identical. This is likely due to the fact that both
factors in part utilize a common βKlotho-dependent mechanism of
FGFR activation, and suggest that FGF19 and FGF21 may share
overlapping functions in metabolic regulation. However, a critical
pharmacological feature that differentiates both factors is that FGF21
is nonmitogenic [5] and may even delay tumor formation [20],
whereas FGF19 transgenic mice develop hepatocellular carcinomas
[23]. The latter has been recently suggested to be mediated via FGFR4
activation in the liver [24].
3. FGF21
FGF21 is produced and possibly secreted in active form by
peripheral tissues such as liver, pancreas, adipose, and skeletal muscle
[25–28]. The expression of FGF21 in these tissues is regulated by
critical pathways involved in metabolic regulation including PPARα,
PPARγ [27,29,30] and Akt-dependent signaling [25], consistent with
the role of FGF21 as an energy homeostasis controller.
Similar to the biology of many other metabolic hormones, FGF21
level in general circulation is responsive to the energy state of the
body. Prolonged fasting and activation of PPARα, a transcriptional
regulator of fasting adaptations, induce hepatic FGF21 expression and
plasma FGF21 levels [29,30], supporting involvement of FGF21 in
fasting-induced response. The role of PPARα in the FGF21 expression is
suggested by the PPARα recognition sites on the FGF21 gene promoter[30], and the ﬁndings that PPARα knockout mice failed to respond to
fasting- or PPARα agonist-induced hepatic FGF21 expression [29,30].
The PPARα-mediated FGF21 expression during fasting is presumably
physiologically induced via activation of PPARα by free fatty acid, an
energy substrate that is elevated when plasma glucose and insulin
decline. Insulin and glucagon, two primary hormonal switches
between feeding and fasting conditions have also been shown to
regulate FGF21 expression and its levels in blood of rodents. In isolated
primary hepatocytes, glucagon induces FGF21 expression whereas
insulin has an inhibitory role [31]. In muscle and fat cells, however,
insulin stimulates FGF21 expression [25]. In glucagon receptor
knockout mice, fasting or exercise is unable to induce a normal level
of hepatic FGF21 expression [32], supporting the notion that glucagon
elevates hepatic FGF21 expression in vivo. Total lack of glucagon action
in glucagon receptor knockout mice, however, also leads to the
elevated FGF21 expression in liver, suggesting rather an inhibitory role
of glucagon signaling in FGF21 production [33].
FGF21mediatesmetabolic changes such as elevation of hepatic lipid
oxidation, ketogenesis and gluconeogenesis [29,30,34] that are remi-
niscent of the body's adaptation to fasting state. Liver-speciﬁc FGF21
transgenic mice exhibited increased hepatic ketone production and
decreased triglyceride storage, which is associated with enhanced
expression of key genes involved in ketogenesis and lipid metabolism
[30]. Under ketogenic diet, adenovirus-mediated knockdown of hepatic
FGF21 inmice results in liver steatosis and elevated plasma triglyceride,
concomitantwith a reduction in the expression of genes critical for lipid
metabolism [29]. However, the physiological consequences of whole-
body FGF21 ablation differ signiﬁcantly, based on the ﬁndings of three
independently generated knockout models [34–36]. When fed a
ketogenic diet for 28–30 weeks, mice lacking FGF21 developed fatty
liver, hypertriglyceridemia, increased serum free fatty acids and
cholesterol, impaired ketogenesis, glucose intolerance and insulin
resistance [35]. However, another cohort of FGF21 null mice on
8 weeks of normal chow displayed reduced fasting plasma free fatty
acids level, with no other metabolic derangement [36]. Finally, a third
line of FGF21 null animals of undisclosed age and diet regimen had
elevated fasting free fatty acids and mild hypoglycemia [34]. Although
thediscrepancies in themice phenotypes require reconciliation through
further research, it may be the results of differences in the animal age,
diet, genetic background and experimental procedures. Indeed, the
most striking phenotype of FGF21 knockoutmicewas observed in older
animals fed a ketogenic diet [35], as compared to youngermice without
a dietary challenge [34,36].
The tissue-speciﬁc metabolic action of FGF21 on liver, adipose
tissue and pancreas is achieved by restrictive expression of βKlotho, a
single-pass transmembrane protein which is essential for FGF21
signaling [5,37,38]. However, itwas reported that FGF21 induced Egr-1
transcriptional activation in white and brown adipose tissues of
βKlotho knockout mice [17]. The report proposed the possibility of a
βKlotho-independent pathway for FGF21 signaling [17]. Nonetheless,
it remains to be studied whether the ﬁnding is valid for more
integrated metabolic actions of FGF21 beyond signaling, or the
observation [38] is simply a reﬂection of secondary systemic effects.
Indeed, the recent report on adipose-speciﬁc deletion of βKlotho
indicates that the anti-obesity effect of FGF21 treatment is completely
abolished in mice [39], supporting the critical role of βKlotho to
propagate FGF21 signal. Several potential downstream mediators of
the FGF21 have been reported recently. In the liver, FGF21 induces the
expression of peroxisomeproliferator-activated receptorγ coactivator
1α (PGC1α), a critical transcriptional regulator of fatty acid oxidation,
mitochondrial function and gluconeogenesis [34]. In cultured adipo-
cytes, FGF21 is shown to activate AMP-activated protein kinase
(AMPK), and sirtuin 1 (SIRT1) which deacetylate PGC1α to increase
mitochondrial gene expression and oxidative capacity [40]. This is
consistent with the elevation of whole body energy expenditure, and
reduction of adiposity and hepatic steatosis in FGF21-treated mice
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function and survival [28], and to protect pancreatic acini cells against
injury [42].
While FGF21 appears to be therapeutically beneﬁcial in rodent
studies, it is however unclear how much of these ﬁndings will
translate to human background as some fundamental differences in
FGF21 function in rodents and humans have already been noted. For
example, in mouse models FGF21 has been shown to induce lipolysis
in adipocytes, hepatic ketogenesis and state of torpor [29,30]. All of
the above does not seem to be the case in human background. Indeed,
FGF21 has been shown to inhibit lipolysis in human adipocytes [43].
Further, in humans the induction of ketogenesis appears to be
independent of FGF21, FGF21 does not reveal a pronounced diurnal
rhythm, and FGF21 protein in plasma is increased only after extreme
fasting condition for 7 days [44]. Finally, given that torpor is an
adaptive metabolic response in small mammals, the direct extrapo-
lation of FGF21 rodent biology to man may be largely misleading.
A critical feature of FGF21 metabolic action is its capacity to
sensitize insulin action in vivo. Systemic administration of FGF21 in
mice reduces plasma glucose and triglyceride, enhances insulin
sensitivity, and lowers obesity and hepatosteatosis [22,29,41]. In
diabetic rhesus monkeys, FGF21 treatment caused a marked amelio-
ration in fasting plasma glucose, fructosamine, triglycerides, insulin,
and glucagon [45]. Chronic FGF21 treatment of ob/ob mice improved
fasting hyperglycemia via improved hepatic insulin sensitivity and
decreased liver glucose production [46]. Interestingly, neither chronic
nor acute FGF21 treatment altered skeletal muscle glucose uptake in
the ob/ob mouse model, consistent with the lack of βKlotho in this
tissue [46]. The insulin-sensitizing effects of FGF21 are apparent in
animals that display themetabolic syndrome or insulin resistance, but
otherwise FGF21 does not affect metabolism in normal animals.
Therefore, the attractive preclinical safety features of FGF21 include
absence of hypoglycemia, lipodystrophy, edema and excessive weight
loss [47]. Despite the wealth of data on the therapeutic effects of this
peptide, the molecular mechanism for FGF21 insulin-sensitizing
effects is not fully understood but may be related to the observed
elevation of insulin receptor expression in peripheral tissues [22].
Elevation of circulating FGF21 to a modest 1.5-fold to 2-fold is
observed in diabetic, obese, and dyslipidemic individuals, and
appeared to correlate with reduced insulin sensitivity and HDL-
cholesterol as well as clinical signs of metabolic syndrome including
increased adiposity, blood glucose, insulin and triglycerides
[44,48,49]. These ﬁndings suggest that elevated FGF21 may manifest
a possible physiological response to compensate for cellular resistance
to FGF21 action in ametabolically compromised state. Consistent with
the notion of FGF21 resistance, the acute effect of FGF21 on signaling
andmetabolic responses is indeed impaired in diet-induced obese and
diabetic ob/ob mice [46,50]. It remains therefore unclear why these
animals showed apparent metabolic improvement upon chronic
treatment at therapeutic doses of FGF21 [22,41,46], or whether
prolonged FGF21 therapy would eventually lead to desensitization of
this therapeutic in man.
4. FGF23
Since FGF23 gene was discovered mutated in patients with
autosomal dominant hypophosphatemic rickets, FGF23 has been
identiﬁed as a critical hormonal regulator of phosphate homeostasis
[8]. In this genetic disorder, the mutation in a subtilisin-like proprotein
convertase cleavage site in FGF23 renders the protein resistant to
proteolysis, leading to increased half-life of active FGF23 in blood and
eventual hypophosphatemia [8]. Conversely, attenuation of FGF23
signaling caused by missense mutations in the gene leads to familial
tumoral calcinosis with hyperphosphatemia calcinosis in humans [51].
Elevated FGF23 levels are also found in patients with X-linked
hypophosphatemic rickets osteomalacia [52]. In patients with chronicrenal disease, FGF23 is increased by100- to 1000-fold, and its circulating
levels appeared to inversely correlate with renal function [53].
While FGF23 expression is detected in multiple tissues [54], the
protein is primarily produced in thebone [55] fromwhich it circulates to
regulate phosphate and vitamin D metabolism in the kidney. In FGF23-
transgenic mice, renal phosphate reabsorption is decreased [56,57],
caused by lower levels of sodium/phosphate cotransporter type IIa and
IIc in the kidney [58,59]. FGF23 also reduces plasma phosphate
concentration by suppressing the CYP27B1/CYP24 pathway-mediated
productionof 1, 25-dihyroxyvitaminD level, the active formof vitaminD
which facilitates intestinal phosphate absorption [58,60]. In corrob-
orationwith these ﬁndings, animalswith genetic ablation of FGF23 in
mice display high plasma phosphate, calcium and 1, 25-dihyroxyvita-
min D levels, impaired bone mineralization, calciﬁcation of soft tissues
including kidney and vasculature, and shortened life-span [61]. Taken
together, the human and mouse genetic and pathophysiologic data
highlight the primary function of FGF23 as a hormone of phosphate and
vitamin D metabolism.
The ability of FGF23 to target kidney via bone-kidney axis of cross-
tissue communication is determined by high renal expression of its
coreceptor Klotho that is enriched in distal convoluted tubules where
the early response to FGF23 takes place. Nonetheless, FGF23-
regulated phosphate homeostasis and vitamin D metabolism are
localized in the far distant proximal tubules, suggesting the presence
of a distal-to-proximal communication in FGF23 renal action that
mechanistically may involve additional molecular partners such as
soluble Klotho. FGF23 binds to Klotho via its C-terminus and this
interaction is required for activation of FGFR [6,62]. In amutantmouse
model of hypophosphatemia (Hyp mice), genetic inactivation of
Klotho is able to induce hyperphosphatemia even in the presence of
high circulating FGF23 levels [63]. The requirement of Klotho in
FGF23-mediated phosphate homeostasis is further supported by the
ﬁndings that FGF23 treatment failed to lower serum phosphate in
Klotho knockout mice and FGF23/Klotho double knockout mice [63].
Although FGFR1c/Klotho complex has been proposed to constitute a
canonical renal FGF23 receptor [59], FGF23 may mediate its signal via
several other FGFRs [6]. Therefore, FGF23 receptor speciﬁcity is
determined by Klotho, consistent with the absence of renal phenotype
in animals with ablation of speciﬁc FGFR isoforms [64].
FGF23 also acts directly on the Klotho-expressing parathyroid gland
to inhibit the secretion parathyroid hormone (PTH) which increases
vitamin D activation and elevates intestinal phosphate absorption.
Interestingly, elevated levels of FGF23 and Klotho are associated with
hyperparathyroidism [65,66], which may be due to altered metabolism
of vitamin D or direct regulation of FGF23 expression by PTH. Knockout
mouse models provided evidence that FGF23 is required for skeletal
mineralization and normal bone development [61,67], and the action is
independent of its serum phosphate functions [67]. Given the
expression of Klotho in the reproductive organs, brain, choroid plexus,
and pituitary, there may be physiological role of FGF23 in these tissues
which remains to be demonstrated [68].
5. Conclusions
FGF19, FGF21 and FGF23 are present systemically in the blood and
may act on respective target tissues through tissue-speciﬁc expres-
sion of their Klotho coreceptors. These hormone-like FGFs hold the
major promise for therapeutic development among other FGF family
members. FGF21 is leading in clinical development owing to its
disease-modifying pharmacology and remarkable safety proﬁle in
animal studies that is yet to be conﬁrmed in humans [69]. Although
FGF19 is also an attractive drug candidate, the development of
hepatocellular carcinoma in aged FGF19 transgenic mice [23]
positions this factor as a drug target for cancer [70,71] rather than a
viable therapeutic for the treatment of chronic metabolic disorders.
Targeting FGF23 may have a therapeutic beneﬁt for the treatment of
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established [8,51,52], and neutralizing antibodies against FGF23
ameliorate phosphate and vitamin D metabolism in mice [72]. The
elevation of FGF23 in chronic renal disease points to the possibility of
this protein to be involved in the pathophysiology of this disease in
man [53]. However, it still remains uncertain whether FGF23 action
needs to be pharmacologically inhibited or activated given the
positive correlations between serum FGF23 levels with poor progno-
sis in patients with end-stage renal disease [73]. The role of FGF23 in
renal diseases therefore requires further clariﬁcation. Given the broad
spectrum effects endocrine-like FGFs have on metabolic regulation,
the pharmacological signiﬁcance of FGF19, FGF21, and FGF23-based
therapeutics encompassing recombinant proteins and/or neutralizing
antibodies need to be ultimately explored in the future.References
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